Form 8-K - Current report:
SEC Accession No. 0001140361-24-041663
Filing Date
2024-09-23
Accepted
2024-09-23 16:34:26
Documents
14
Period of Report
2024-09-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20036156x1_8k.htm   iXBRL 8-K 44717
2 EXHIBIT 2.1 ny20036156x1_ex2-1.htm EX-2.1 1023944
  Complete submission text file 0001140361-24-041663.txt   1424370

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA roiv-20240917.xsd EX-101.SCH 3862
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20240917_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20240917_pre.xml EX-101.PRE 16042
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20036156x1_8k_htm.xml XML 4218
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON D0 HM11
Business Address CLARENDON HOUSE, 2 CHURCH STREET HAMILTON HM11 D0 HM11 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 241316607
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)